Addex Therapeutics Ltd's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Addex Therapeutics Ltd's ROA in the fourth quarter of 2025?
Addex Therapeutics Ltd recorded a cumulative net loss of $-11 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -166.51%.

However, within the Healthcare sector 825 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4972.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	-40.4 %	-45.95 %	-45.95 %	-45.95 %	130.04 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-11	4	4	21	19
Return On Assets (TTM)	-166.51 %	55.7 %	47.14 %	203.11 %	162.78 %
ADXN's Total Ranking	# 4972	#	#	#	# 78
Total Assets (TTM) in million	6	6	6	6	11
Seq. Total Assets Change	0 %	0 %	0 %	-40.4 %	-9.32 %
Seq. Net Income Change	-	-	-	-	-

ADXN's 5 Years Annual ROA >> Back to ADXN Management Effectiveness >> Compare ADXN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 383
Sector	# 826
Overall	# 4929

Return On Assets Statistics
High	Average	Low
66.08 %	-106.77 %	-251.2 %
(Dec 31 2024)		(Dec 31 2022)

Financial Statements
Addex Therapeutics Ltd's Assets	$ 6 million	ADXN's Balance sheet
Addex Therapeutics Ltd's Income	$ -7 million	Quarterly ADXN's Income Statement
ADXN's Income by Division		See ADXN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-40.4 %	130.04 %	-43.95 %	-66.4 %	7.97 %
Total Assets in million	6	11	5	8	25
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-7	7	-11	-21	-15
Annual Return On Assets	-105.72 %	66.08 %	-227.41 %	-251.2 %	-62.29 %

ADXN's 5 Years Annual ROA >> Back to ADXN Management Effectiveness >> Compare ADXN ROA to its Competitors

More Return On Assets Ratios
ADXN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ADXN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ADXN's Competitors
Subscribers only: Roa for Addex Therapeutics Ltd's Suppliers
Subscribers only: Return On Assets for ADXN's Customers

You may also want to know
ADXN's Roi	ADXN's Inventory Turnover Ratio	ADXN's Growth Rates	ADXN's Dividend Comparisons
	ADXN's Profitability Ratios	ADXN's Asset Turnover Ratio	ADXN's Dividend Growth
ADXN's Roe	ADXN's Valuation Ratios	ADXN's Financial Strength Ratios	ADXN's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.